posit start
erratum replac report publish januari incorrectli
state front page target price averag dcf
price-to-earnings ev/ebitda multipl correct dcf
price-to-earnings also correct figur show blend valuat averag
increas ebit estim average target price
organ growth ebit margin
also slightli compani guidanc exit rate organ growth across household
care food beverag bioenergi margin run rate
suggest posit earn risk opinion bioag bioenergi macro/trad
deal risk also appear skew upsid sever weather us middl east
issu provid larg unchalleng compar base result
demonstr spite weaker end market demand novozym innov project
continu support growth roll-out new manag improv
trajectori
drive organ growth believ key driver behind return
mid-singl digit organ growth surround continu roll-out new product across
fresh probiot yeast ethanol palm oil exit rate ethanol product
crush spread posit yoy respect
support bioenergi earn albeit acknowledg like volatil
middl eastern cyclic headwind currenc local demand issu export restrict
headwind throughout abat north american agricultur
posit develop weather depend redeploy cost save
focus lower risk also margin support drive growth
medium term restor mid-singl digit organ growth emerg trough
year believ compani prove recent issu cyclic restor
investor confid innov busi model close valuat gap peer
valuat target price repres averag dcf
price-to-earnings multipl ev/ebitda multipl
valuat metric
number share
price rel chart measur perform
omxc close
spot exchang rate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
price
novozym a/ denmark-bas biotechnolog compani engag
product sale industri enzym microorgan
biopharmaceut ingredi compani busi consist two
return peak oil corn would gener
organ growth could justifi novozym rerat toward histor pe
premium
trough oil cse would gener organ growth could
justifi novozym derat toward low end histor pe trade
price rel chart measur perform omxc close
spot exchang rate
upgrad forecast ebit averag organ growth
increas across bioenergi household care food beverag forecast
increas across divis function increas run rate vs prior
expect beat vs cs household bioenergi
respect margin upgrad function oper leverag drop
ahead consensu base view restructur save fulli
reinvest busi due ceo chang
figur credit suiss earn forecast chang novozym
forecast organ earn growth fy highlight tabl
impair bioag
element organ growth forecast includ
currenc assum dkr headwind dkr strengthen vs usd led
restructur expens novozym took restructur charg
expect restructur charg
save estim result
restructur novozym save
result increment dkr save howev
believ reinvest busi onward assum save
fall ebit
defer revenu novozym receiv defer revenu light
termin agreement monsanto addit deal payment
expect recur
bioag write-down novozym took write-down bioag cse
expect recur
pharma sale novozym sold royalti stream within nical
pharma busi dkr addit gain sale
dkr expect recur
target price dkr round averag multipl pe valuat dkr
multipl ev/ebitda valuat dkr dcf dkr
dcf valuat dkr highlight tabl
fy ev/ebitda pe valuat highlight tabl
dcfderiv debt cash market cap share valu per share cash-flow first cash-flow forecast profit back depreci post increase/add decreas cash-flow firm rate wacc discount factor factor start first forecast discount valu ev charl martineau pm univers toronto januari
highlight month forward consensu ev/ebitda novozym trade
premium peer premium year averag vs peer
month forward consensu price-to-earnings novozym trade premium peer
premium year histor averag vs peer
compani mention price
samuel perri cfa chri counihan charl bentley certifi respect compani secur individu analyz
view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
